First Time Loading...

Hisamitsu Pharmaceutical Co Inc
TSE:4530

Watchlist Manager
Hisamitsu Pharmaceutical Co Inc Logo
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Watchlist
Price: 3 823 JPY 1.16%
Updated: Apr 30, 2024
Section:
 

Relative Value

The Relative Value of one Hisamitsu Pharmaceutical Co Inc stock under the Base Case scenario is 3 480.72 JPY. Compared to the current market price of 3 823 JPY, Hisamitsu Pharmaceutical Co Inc is Overvalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3 480.72 JPY
Overvaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
98
vs Industry
53
Median 3Y
2.4
Median 5Y
2.7
Industry
2.4
Forward
2
More Details
20.3
P/E
P/E
Price to Earnings
20.3
vs History
84
vs Industry
25
Median 3Y
28.5
Median 5Y
25
Industry
22.9
Forward
19.1
More Details
23.4
P/OCF
P/OCF
Price to OCF
23.4
vs History
39
vs Industry
20
Median 3Y
23
Median 5Y
22.7
Industry
17.1
More Details
138.3
P/FCFE
P/FCFE
Price to FCFE
138.3
vs History
22
vs Industry
5
Median 3Y
61.8
Median 5Y
31.1
Industry
23.2
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
95
vs Industry
60
Median 3Y
1.2
Median 5Y
1.4
Industry
2.1
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
84
vs Industry
69
Median 3Y
1.3
Median 5Y
1.7
Industry
2.6
Forward
1.1
More Details
2.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.1
vs History
82
vs Industry
71
Median 3Y
2.3
Median 5Y
2.7
Industry
5.1
More Details
8.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.2
vs History
90
vs Industry
40
Median 3Y
11.1
Median 5Y
10.6
Industry
13.6
Forward
7.7
More Details
11
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11
vs History
82
vs Industry
37
Median 3Y
15.9
Median 5Y
14.3
Industry
17
More Details
13.5
EV/OCF
EV/OCF
Enterprise Value to OCF
13.5
vs History
46
vs Industry
31
Median 3Y
12.5
Median 5Y
12.8
Industry
15.8
More Details
76.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
76.4
vs History
22
vs Industry
7
Median 3Y
32.5
Median 5Y
18.5
Industry
17.6
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
93
vs Industry
63
Median 3Y
1
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Hisamitsu Pharmaceutical Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
291B JPY 2.1 20.3 8.2 11
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
699.9B USD 20.5 133.6 60.3 69.3
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 17.4 48.5 35.4 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
353.4B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.5 902.5 44.8 87.6
UK
AstraZeneca PLC
LSE:AZN
187.9B GBP 5.1 39.6 140.8 225.8
CH
Novartis AG
SIX:NOVN
182B CHF 4.3 13.5 9.8 16.3
CH
Roche Holding AG
SIX:ROG
175.2B CHF 3 15.2 8.7 10.3

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.